Company intelligence / Profile preview
PiMedBio
Not specified, Gyeonggi-do, South Koreapimedbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PiMedBio is developing first-in-class oncology therapeutics, with its lead asset PMB212 targeting cancer stemness. The company leverages a proprietary platform to identify optimal drug candidates, focusing on precise molecular and cellular targets involved in disease progression. As of early 2025, its most advanced programs are in preclinical or discovery stages, with no clinical trial results yet reported[2][3].
- Therapeutic areas
- OncologyImmunologyGastroenterology
- Modalities
- Small molecule drugsBiological products[3]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major partnerships disclosed as of May 2025. Participated in JLABS Korea innovation ecosystem, which may indicate collaborations or incubator support[4].
Beyond the preview
Go deeper on PiMedBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PiMedBio.